Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the ...

with manageable hyperkalemia risks through protocolized monitoring and dose adjustments, maintaining clinical benefits even ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

While exercise is generally beneficial for a person's overall health, physical activities may increase the risk of adverse ...

An immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant in a Stanford ...

SGLT-2I therapies reduce the risk of heart failure and this study clearly demonstrates the benefit of adding them onto ...

Study links hallucinogen use to higher schizophrenia risk, highlighting the need for caution and informed decisions on ...

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

Nothing about pregnancy diminishes an individual’s decision-making capacity or obviates their right to make decisions related ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight ...